Company · CIK 1841387
Candel Therapeutics, Inc.
| CIK | 1841387 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2836 — Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
| Business address | MA |
| Listed | CADL (Nasdaq) |
| First annual or quarterly report | 2021-09-08 |
Offerings
3 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-289595 | 2025-08-14 | 2026-02-20 | 4 | |
| 333-266605 | 2022-08-05 | 2025-06-24 | 7 | |
| 333-257444 | 2021-06-25 | 2021-07-28 | 6 |
Filings
18| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2026-02-20 | 424B5Shelf takedown | 333-289595 | 0001193125-26-061389 |
| 2026-02-19 | 424B5Shelf takedown | 333-289595 | 0001193125-26-059514 |
| 2025-08-22 | EFFECTDeclared effective | 333-289595 | 9999999995-25-002727 |
| 2025-08-14 | S-3Shelf registered | 333-289595 | 0001193125-25-180411 |
| 2025-06-24 | 424B5Shelf takedown | 333-266605 | 0001193125-25-145401 |
| 2024-12-13 | 424B5Shelf takedown | 333-266605 | 0001193125-24-278628 |
| 2024-12-12 | 424B5Shelf takedown | 333-266605 | 0001193125-24-277171 |
| 2024-05-24 | 424B5Shelf takedown | 333-266605 | 0001193125-24-146526 |
| 2024-02-13 | 424B5Shelf takedown | 333-266605 | 0001193125-24-032997 |
| 2022-08-12 | EFFECTDeclared effective | 333-266605 | 9999999995-22-002371 |
| 2022-08-05 | S-3Shelf registered | 333-266605 | 0001193125-22-213718 |
| 2021-07-28 | 424B4Final prospectus | 333-257444 | 0001193125-21-227369 |
| 2021-07-26 | EFFECTDeclared effective | 333-257444 | 9999999995-21-002918 |
| 2021-07-26 | S-1/AAmendment | 333-257444 | 0001193125-21-223611 |
| 2021-07-21 | S-1/AAmendment | 333-257444 | 0001193125-21-219850 |
| 2021-07-16 | S-1/AAmendment | 333-257444 | 0001193125-21-216891 |
| 2021-06-25 | S-1Registration filed | 333-257444 | 0001193125-21-200639 |
| 2021-02-16 | DRSDraft made public | 377-04235 | 0000950123-21-002069 |